Cardiovascular metabolic system diseases have become a global health crisis, affecting the quality of life and health status of people.
Cardiovascular Diseases are a group of disorders of the heart and blood vessels, which are the leading cause of death globally. An estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. Youngen provides professional heart disorder treatment as one of the leading biopharmaceutical companies.
The umbrella term “metabolic diseases” includes hypertension, type 2 diabetes mellitus, hyperlipidemia , obesity, and non-alcoholic fatty liver disease, which is drawing increasing awareness. Many of these diseases occur together, share common risk factors, and are associated with increased risks of disability, cancer, and premature deaths.
If you want to know more about cardiovascular pharmacotherapy and metabolic treatment, please visit our website.
Youngen, based in Beijing, is a biopharmaceutical limited pioneering the development of next-generation siRNA drugs to silence specific mRNAs and reduce the production of proteins that cause diseases.
You must be logged in to post a comment.